Sitagliptin Vildagliptin And Saxagliptin Dipeptidyl Peptidase

CLOSE
PDF
DOC
PPT
Sitagliptin, vildagliptin and saxagliptin — dipeptidyl ...

Sitagliptin, vildagliptin and saxagliptin — dipeptidyl ...

Sitagliptin, vildagliptin and saxagliptin NPS RADAR | FEBRUARY 2013 NPS Better choices Better health 4 How does it compare? Gliptins improve glycaemic control in patients
Thu, 21 Aug 2014 15:45:00 GMT
Sitagliptin (JANUVIA®) - RxFiles | Drug Index

Sitagliptin (JANUVIA®) - RxFiles | Drug Index

RxFiles: Q&A Summary www.RxFiles.ca - Nov, 2008 Rene Breault BScPharm, PharmD Candidate; L. Regier BSP BA, B. Jensen BSP Sitagliptin (JANUVIA®)
Thu, 21 Aug 2014 20:17:00 GMT
Advice from the Scottish Medicines Consortium relevant to ...

Advice from the Scottish Medicines Consortium relevant to ...

Advice from the Scottish Medicines Consortium relevant to SIGN 116 – Management of Diabetes (correct at 26 April 2011) 1 Drug Manufacturer Date
Thu, 21 Aug 2014 20:25:00 GMT
New Drugs in Development for the Treatment of Diabetes

New Drugs in Development for the Treatment of Diabetes

92 Diabetes Spectrum Volume 22, Number 2, 2009 In Brief A variety of new agents are in development for the treatment of type 1 or type 2 diabetes.
Tue, 19 Aug 2014 23:26:00 GMT
Stellungnahme der Deutschen Diabetes Gesellschaft (DDG) zu ...

Stellungnahme der Deutschen Diabetes Gesellschaft (DDG) zu ...

kritische und fachübergreifende Stellungnahme zusammen mit der Deutschen Gesellschaft für Innere Medizin (DGIM), der Deutschen Gesellschaft für Kardiologie (DGK ...
Fri, 22 Aug 2014 02:37:00 GMT
Incretine e gliptine: nuove opportunità terapeutiche e ...

Incretine e gliptine: nuove opportunità terapeutiche e ...

Incretine e gliptine: nuove opportunità terapeutiche e criticità 15 ce, coinvolgere il sistema immunitario [31, 32]. La stimolazione del rilascio di insulina
Thu, 21 Aug 2014 21:22:00 GMT
Comparison of efficacy between incretin-based therapies ...

Comparison of efficacy between incretin-based therapies ...

comparative trials analyzing efficacy, tolerability and safety profiles between the agents from these two classes. Physiology of incretins The classic ‘incretin ...
Thu, 21 Aug 2014 00:44:00 GMT
Launch Excellence in the Diabetes Market - IMS Health

Launch Excellence in the Diabetes Market - IMS Health

WHITE PAPER | DIABETES LAUNCH EXCELLENCE Launch Excellence in the Diabetes Market Lessons from History
Wed, 20 Aug 2014 01:56:00 GMT
Australian Public Assessment Report for Linagliptin

Australian Public Assessment Report for Linagliptin

Australian Public Assessment Report for Linagliptin Proprietary Product Name: Trajenta Sponsor: Boehringer Ingleheim (Australia) Pty Ltd December 2011
Wed, 20 Aug 2014 19:00:00 GMT
CHMP ASSESSMENT REPORT FOR Onglyza - European Medicines Agency

CHMP ASSESSMENT REPORT FOR Onglyza - European Medicines Agency

Page 5 of 57 2 SCIENTIFIC DISCUSSION 2.1 Introduction Type 2 Diabetes Mellitus (T2DM) is a common chronic metabolic disorder, which can lead to
Thu, 21 Aug 2014 17:04:00 GMT